RNA-based biomarker to determine biological response

The Belgian biotech company argenx is currently running a clinical trial of ARGX-110, a first-in-class SIMPLE antibody targeting CD70, an immune checkpoint target involved in hematological malignancies, solid tumors and severe autoimmune diseases.

To determine the biological response to ARGX-110, Biogazelle has developed and validated an RT-qPCR-based test for accurate and sensitive CD70 mRNA measurement on whole blood. Measurement of this RNA biomarker on samples coming from their clinical study (currently in phase 2a) is also performed at Biogazelle.

"argenx is a clinical stage human monoclonal antibody therapeutics company. Our business model relies on outsourcing and Biogazelle is our outsourcing partner to set-up and perform mRNA analyses in both the pre-clinical and clinical phases of our running projects.
We selected Biogazelle because they have a decade of experience in real-time PCR experiment design, assay development and data-analysis. The scientific support by Biogazelle's project manager has been outstanding. I would recommend Biogazelle as a solid service provider with a highly professional and personal approach."

- Karen Silence, PhD, project manager ARGX-110

RNA-based diagnostic test for MS patient stratification

GeNeuro has developed the antibody GNbAC1 as therapeutic in Multiple Sclerosis (MS), and a Phase IIb study is currently running. geNeuro wanted Biogazelle to develop an RNA-based test to stratify MS patients that will likely benefit from a treatment with GNbAC1.

To this end, Biogazelle is currently validating an RT-qPCR based method for accurate measurement of MSRV-Env (Multiple Sclerosis associated retrovirus envelope protein) in peripheral blood mononuclear cells (PBMCs). Pending successful development of the method, Biogazelle will perform the MSRV-Env RNA quantification of the phase 2 and phase 3 clinical trial samples.

Development of PrimePCR qPCR assay portfolio

Biogazelle developed the most comprehensive portfolio of validated Research Use Only (RUO) qPCR assays for human, mouse, rat. The assays are commercialized by Bio-Rad under the PrimePCR brand. Assay development was performed using our primerXL pipeline incorporating state-of-the-art in silico assay validation. All qPCR assays were wet lab validated (including deep amplicon sequencing to confirm specificity) and come with a validation report.

The PrimePCR catalog currently contains more than 312 000 assays, including in silico validated assays for 10 additional model organisms. As the collaboration with Bio-Rad continues, the PrimePCR catalog will be further expanded with RT-qPCR assays for 60,000 human lncRNAs.

Bio-Rad product page